| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 13.86% | Stifel | $14 → $16 | Maintains | Buy |
| 10/17/2023 | 6.74% | Wells Fargo | $13 → $15 | Maintains | Equal-Weight |
| 10/17/2023 | 13.86% | BMO Capital | → $16 | Downgrades | Outperform → Market Perform |
| 10/16/2023 | 6.74% | Wells Fargo | → $15 | Upgrades | Underweight → Equal-Weight |
| 10/10/2023 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 10/03/2023 | 13.86% | Wedbush | → $16 | Initiates Coverage On | → Outperform |
| 09/20/2023 | 6.74% | Jefferies | $11 → $15 | Upgrades | Hold → Buy |
| 08/11/2023 | -0.38% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
| 07/27/2023 | -7.49% | Berenberg | → $13 | Initiates Coverage On | → Hold |
| 07/14/2023 | -11.05% | Citigroup | $11 → $12.5 | Maintains | Neutral |
| 04/25/2023 | -7.49% | Barclays | $15 → $13 | Maintains | Equal-Weight |
| 04/20/2023 | -21.72% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/19/2023 | -21.72% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/12/2023 | -7.49% | Credit Suisse | → $13 | Reiterates | → Neutral |
| 03/29/2023 | -7.49% | Truist Securities | $14 → $13 | Maintains | Buy |
| 03/28/2023 | -25.28% | Citigroup | $13 → $10.5 | Maintains | Neutral |
| 12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 11/14/2022 | -7.49% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
| 10/10/2022 | -7.49% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 06/30/2022 | -0.38% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
| 05/25/2022 | 6.74% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
| 04/18/2022 | -0.38% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
| 04/04/2022 | 6.74% | Credit Suisse | $14 → $15 | Maintains | Neutral |
| 03/11/2022 | 6.74% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
| 02/23/2022 | 28.09% | Stifel | $21 → $18 | Maintains | Buy |
| 02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 02/01/2022 | -0.38% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 09/30/2021 | 28.09% | Truist Securities | → $18 | Upgrades | Hold → Buy |
| 09/13/2021 | 42.32% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
| 05/21/2021 | 49.44% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
| 05/10/2021 | 49.44% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
| 01/13/2021 | 42.32% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
| 01/08/2021 | 35.21% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
| 12/03/2020 | 70.79% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
| 09/02/2020 | 6.74% | Stifel | → $15 | Reinstates | → Hold |
| 06/23/2020 | 6.74% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
| 06/22/2020 | -0.38% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
| 05/18/2020 | 6.74% | Berenberg | → $15 | Upgrades | Hold → Buy |
| 04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
| 04/07/2020 | -28.84% | Citigroup | $20 → $10 | Maintains | Neutral |
| 03/26/2020 | -25.28% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
| 02/26/2020 | 56.55% | Mizuho | → $22 | Upgrades | Neutral → Buy |
| 02/06/2020 | 77.9% | Barclays | $26 → $25 | Maintains | Overweight |
| 02/05/2020 | 56.55% | Berenberg | → $22 | Initiates Coverage On | → Hold |
| 12/20/2019 | 56.55% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
| 12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
| 09/27/2019 | 63.67% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 09/23/2019 | 42.32% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
| 09/03/2019 | 70.79% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
| 12/17/2018 | 35.21% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
| 11/16/2018 | 49.44% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
| 11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/13/2018 | 49.44% | Mizuho | → $21 | Downgrades | Buy → Neutral |
What is the target price for Sabra Health Care REIT (SBRA)?
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by Stifel on November 7, 2023. The analyst firm set a price target for $16.00 expecting SBRA to rise to within 12 months (a possible 13.86% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by Stifel, and Sabra Health Care REIT maintained their buy rating.
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a maintained with a price target of $14.00 to $16.00. The current price Sabra Health Care REIT (SBRA) is trading at is $14.05, which is within the analyst's predicted range.